Bevacizumab

Oncologist

Volumn 15, Issue 8, 2010, Pages 819-825

  Kazazi Hyseni, Filis ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Angiogenesis; Anti VEGF monoclonal IgG1 antibody; Bevacizumab; Safety

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; RANIBIZUMAB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC MACULAR EDEMA; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOTHELIUM CELL; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTATIC BREAST CANCER; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STEM CELL; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956855572     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0317     Document Type: Review

References (47)

1. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-2621.
2. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. Final Labeling Text, BL125085 Supplement, 2008. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf, accessed February 15, 2010.
3. The European Medicines Agency. European Public Assessment Report. Avastin Product Information. Avastin-H-C-582-II-23, August 2008. Available at http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000582/WC500029270.pdf, accessed January 24, 2009.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
6. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
7. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25:1539-1544.
8. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
9. Sandler A, Gray R, Perry MC et al. Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
10. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
11. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-3247.
12. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
13. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008;26:76-82.
14. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010 July 6 [Epub ahead of print].
15. Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
16. Micha JP, Goldstein BH, Rettenmaier MA et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007;17:771-776.
17. Verheul HM, Lolkema MP, Qian DZ et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13:5341-5347.
18. Tanimoto K, Yoshiga K, Eguchi H et al. Hypoxia-inducible factor-1_ polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-1783.
19. Muller YA, Chen Y, Christinger HW et al. VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 1998;6: 1153-1167.
20. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-1802.
21. Herbst RS, O'Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750.
22. Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-3129.
23. Pegram M, Chan D, Dichmann RA et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract S28]. Breast Cancer Res Treat 2006;100(1 suppl):S28.
24. van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
25. Lu JF, Bruno R, Eppler S et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-786.
26. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-378.
27. Stollman TH, Scheer MG, Leenders WP et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008;122:2310-2314.
28. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008;14:178-183.
29. Gaudreault J, Lieberman G, Kabbinavar F et al. Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC). Clin Pharmacol Ther 2001; 69:25.
30. Glade Bender JL, Adamson PC, Reid JM et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2008;26:399-405.
31. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracil- based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205.
32. Kariyazono H, Ohno T, Khajoee V et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 2004;56:953-959.
33. Sachs UJ, Socher I, Braeunlich CG et al. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006;119:83-89.
34. Stevens A, Soden J, Brenchley PE et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-816.
35. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A metaanalysis. JAMA 2008;300:2277-2285.
36. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-485.
37. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. 2008 Safety Alerts for Human Medical Products. Dear Healthcare Professional Letter - Genentech. Available at http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm126434.pdf, accessed December 14, 2008.
38. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002;99: 4349-4354.
39. Cascinu S, Graziano F, Catalano V et al. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clin Exp Metastasis 2000;18:651-655.
40. Longo R, Gasparini G. Challenges for patients selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007;60:151-170.
41. Shaked Y, Bertolini F, Man S et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-111.
42. Willett CG, Boucher Y, Duda DG et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139.
43. Torrisi R, Bagnardi V, Cardillo A et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and /or PgR-positive breast cancer: Clinical and biological activity. Br J Cancer 2008;99:1564-1571.
44. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
45. Waintraub SE, Tuchman V. The role of maintenance bevacizumab in patients with metastatic breast cancer treated with chemotherapy and bevacizumab upon achieving complete response or maximal radiologic response with stable disease. J Clin Oncol 2008;26(20 suppl):12022.
46. Tappenden P, Jones R, Paisley S et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-128, iii-iv.
47. National Institute for Health and Clinical Excellence. TA118 Colorectal Cancer (Metastatic) - Bevacizumab & Cetuximab: Guidance; January 2007. Available at http://www.nice.org.uk/nicemedia/live/11612/33930/33930.pdf, accessed July 29, 2009.